Alpha 2.0
Login Register
» Articles » PMID: 17410020

Safety Profile of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer with Chronic Renal Failure

Overview
Journal J Thorac Oncol
Publisher Elsevier
Specialties Oncology
Pulmonary Medicine
Date 2007 Apr 6
PMID 17410020
Citations 4
Authors
Cesare Gridelli
Paolo Maione
Domenico Galetta
Antonio Rossi
Affiliations
Soon will be listed here.
Citing Articles

Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure.

Fujita K, Matsumoto N, Ishida H, Kubota Y, Iwai S, Shibanuma M Curr Drug Metab. 2019; 20(5):361-376.

PMID: 30947665 PMC: 6700602. DOI: 10.2174/1389200220666190402143125.

Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

Kucharczuk C, Ganetsky A, Vozniak J J Adv Pract Oncol. 2018; 9(2):189-200.

PMID: 30588353 PMC: 6302998.

Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.

Szejniuk W, McCulloch T, Roe O BMJ Case Rep. 2014; 2014.

PMID: 25056302 PMC: 4112306. DOI: 10.1136/bcr-2014-204809.

Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer.

Meriggi F, Zaniboni A Curr Gerontol Geriatr Res. 2010; :348174.

PMID: 20672050 PMC: 2905690. DOI: 10.1155/2010/348174.